Review of the TAIFUN® multidose dry powder inhaler technology

Drug Development and Industrial Pharmacy

Volumn 34, Issue 9, 2008, Pages 960-965

  Overhoff, Kirk A ^a   Clayborough, Robert ^a,b   Crowley, Michael ^a  

^a PharmaForm LLC   (United States)

^b Akela Pharma   (United States)

Author keywords

Breakthrough cancer pain; Dry powder inhaler; Fentanyl; Inhalation; Pulmonary

Indexed keywords

FENTANYL; FENTANYL CITRATE; FENTORA; UNCLASSIFIED DRUG;

CANCER PAIN; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; HUMAN; METERED DOSE INHALER; POWDER INHALER; REVIEW; NEBULIZER; PHARMACEUTICS; POWDER;

NEBULIZERS AND VAPORIZERS; POWDERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 52149111374     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040802154897     Document Type: Review

References (16)

1. Arnolds, S., & Heise, T. (2007). Inhaled insulin. Best Pract. Res. Clin. Endocrinol. Metab., 21, 555-571.
2. Cripps, A., Riebe, M., Schelze, M., & Woodhouse, R. (2000). Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir. Med., 94, S3-S9.
3. Pipeline Insight: Breakthrough Pain - Fast-acting Players Will Capture Majority Market Share. Datamonitor. (2006).
4. Farr, S. J., & Otulana, B. A. (2006). Pulmonary delivery of opioids as pain therapeutics. Adv. Drug Del. Rev., 58, 1076-1088.
5. Hoeben, B. J., Burgess, D. S., McConville, J. T., Najvar, L. K., Talbert, R. L., Peters, J. I., Wiederhold, N. P., Graybill, J. R., Bocanegra, R., Overhoff, K. A., Sinswat, P., Johnston, K. P., & Williams III, R. O. (2006). In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother., 50, 1552-1554.
6. Lankinen, T. (1995). Device for more effective pulverization of a powdered inhalation medicament. U.S. Patent No. 5,476,093.
7. Lankinen, T. (1997). Device intended for measuring a dose of powdered medicament for inhalation. U.S. Patent No. RE35,552.
8. Lankinen, T. (2000). Medicament chamber in an inhalation apparatus. U.S. Patent No. 6,132,394.
9. Lankinen, T. (2003). Method for making a pharmaceutical formulations. U.S. Patent No. 6,616,945 B1.
10. Lankinen, T., & Salonen, H. (2006). Method for treating carrier particles and its use. U.S. Patent No. US2006/0025326 A1
11. McConville, J. T., Overhoff, K. A., Sinswat, P., Vaughn, J. M., Frei, B. L., Burgess, D. S., Talbert, R. L., Peters, J. I., Johnston, K. P., & Williams III, R. O. (2006). Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm. Res., 23, 901-911.
12. O'Connor, B. J. (2004). The ideal inhaler: Design and characteristics to improve outcomes. Respir. Med., 98, S10-S16.
13. Sharma, S., White, D., Imondi, A. R., Placke, M. E., Vail, D. M., & Kris, M. G. (2001). Development of inhalational agents for oncologic use. J. Clin. Oncol., 19, 1839-1847.
14. Smith, I. J., & Parry-Billings, M. (2003). The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther., 16, 79-95.
15. Vaughn, J. M., McConville, J. T., Burgess, D. S., Peters, J. I., Johnston, K. P., & Williams III, R. O. (2005). Single dose and multiple dose studies of aerosolized itraconazole nanoparticles. Eur. J. Pharm. Biopharm., 63, 95-102.
16. Virchow, J. C., Crompton, G. K., Dal Negro, R., Pedersen, S., Magnan, A., Seidenbergf, J., & Barnes, P. J. (2008). Importance of inhaler devices in the management of airway disease. Respir. Med., 102, 10-19.